10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

Courtney D. DiNardo, Marina Konopleva, Maro Ohanian et al.|The Lancet Haematology|2020

Cited by 330